Загрузка...
Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib reduced signs and symptoms of atopic dermatitis (AD) in a placebo‐controlled, randomized, double‐blind, phase IIb trial (dose range 10–200 mg). A kinetic‐pharmacodynamic (K‐PD) model consisting of proliferation, maturation, and blood circulation c...
Сохранить в:
| Опубликовано в: : | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577017/ https://ncbi.nlm.nih.gov/pubmed/32830463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12548 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|